CARDIAC · Injectable
VIP + MOTS-c Blend.
Neuroprotective + mitochondrial stack
How it works
Class & mechanism.
In short
The VIP + MOTS-c blend pairs two structurally unrelated peptides with complementary roles: VIP is a neuropeptide studied for anti-inflammatory and neuroprotective signaling, while MOTS-c is a mitochondrial-DNA-encoded peptide studied for activating AMPK and supporting metabolic and insulin-sensitivity pathways. Together they are researched as a dual-axis approach — neural protection alongside cellular energy metabolism — though most supporting evidence is preclinical or drawn from small trials. MOTS-c is currently under FDA Pharmacy Compounding Advisory Committee (PCAC) review (scheduled July 23, 2026), which affects the blend's overall regulatory status.
Class
Neuroprotective & Mitochondrial Metabolic Blend
Mechanism
VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide that acts via VPAC1/VPAC2 receptors to elevate intracellular cAMP, modulate dendritic cells and T-regulatory cells, block peripheral innate immune activation, lower pulmonary artery pressure, and promote astroglia-mediated neuroprotection against excitotoxicity and amyloid toxicity. MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded directly within mitochondrial DNA that translocates to the nucleus under metabolic stress, activating AMPK and the NUPR1-HMOX1 pathway to restore metabolic homeostasis. Together, VIP provides systemic anti-inflammatory and neuroprotective signaling while MOTS-c optimizes mitochondrial bioenergetics and insulin sensitivity — a complementary axis targeting both neural protection and cellular energy metabolism.
Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.
Did you know
MOTS-c is one of only a handful of peptides known to be encoded directly in mitochondrial DNA rather than the nuclear genome — meaning your mitochondria run a hormone-like signaling system that's separate from the rest of your DNA, and levels of it are reported to decline with age, in a pattern researchers have compared to the age-related decline of hormones like testosterone.
Benefits
What it does.
Preclinical evidence indicates VIP-stimulated astroglia signaling may offer neuroprotection against beta-amyloid toxicity and neuroinflammation
MOTS-c's activation of the AMPK pathway in skeletal muscle is studied for its potential to enhance insulin sensitivity and glucose metabolism
VIP's modulation of Th17/Treg balance and IL-10 upregulation may help reduce systemic and neurological inflammation
MOTS-c's AMPK-driven energy sensing may support improved metabolic flexibility and mitochondrial biogenesis
Cardiovascular regulation support: in a small open-label clinical trial, VIP reduced pulmonary artery systolic pressure during exercise; in animal models, MOTS-c protected against pressure overload-induced cardiac hypertrophy
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
What this does not mean
The VIP + MOTS-c blend consists of research chemicals. The information on this page is educational and does not constitute medical advice, diagnosis, or treatment. Neither VIP nor MOTS-c is FDA-approved for treating neuroinflammation, metabolic dysfunction, insulin resistance, or any other use. MOTS-c was removed from FDA Category 2 (Apr 23, 2026) and is currently under Pharmacy Compounding Advisory Committee (PCAC) review, scheduled for July 23, 2026, to determine 503A Bulks List eligibility — this blend's regulatory status tracks the more restrictive MOTS-c component and remains unresolved pending that review. This page does not recommend, endorse, or prescribe any compound for human use. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols or pharmaceutical recommendations.
VIP nasal spray (replacement doses) in 20 patients with chronic inflammatory response syndrome safely reduced refractory symptoms, corrected inflammatory markers, raised VIP and MSH levels, and reduced pulmonary artery systolic pressure during exercise to normal within 2 months — durable response at 18-month follow-up
SOURCE · Scientific Research Publishing (SciRP) — Shoemaker et al., open-label trial in CIRS-WDB patients
MOTS-c treatment improved cardiac function in diabetic rats by enhancing glucose metabolism via NRG1-ErbB signaling, upregulating antioxidant defenses, and restoring mitochondrial bioenergetic function in diabetic hearts
SOURCE · Frontiers in Endocrinology (2022); Frontiers in Physiology (2025) — Li et al. and associated Khavinson-era studies
Circulating MOTS-c levels in young people are 11–21% higher than in middle- and old-aged individuals, and systemic MOTS-c injection in aged mice reversed age-related skeletal muscle insulin resistance and restored MOTS-c to youthful levels
SOURCE · PMC / Frontiers in Endocrinology (2023) — 'MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation'
Protocol
How to use it.
Dosing
VIP: 3–6 units (100–200 mcg) intranasally, 1–2 times daily (standard research protocol). MOTS-c: 5–10 mg subcutaneously, 3–5 times per week. Blend protocols vary; both components are typically administered on the same days. PK data for individual components: VIP has preclinical PK rationale on its product page. MOTS-c has Tier-C dosing rationale detailing the limited rodent PK data. See each component page for absorption and dosing basis.
Cycle
VIP: 30-day treatment periods; reassess response and inflammatory markers before continuing. MOTS-c: 8–12 week cycles; endogenous levels are measured at baseline and post-cycle in research settings. Allow 4–6 weeks between cycles.
Contraindications
When to skip it.
VIP: Caution in patients with low blood pressure (vasodilatory effects). Intranasal route avoids systemic injection risks. MOTS-c may interact with drugs targeting AMPK (e.g., metformin — additive effect). Persistent injection site reactions reported with MOTS-c analog CB4211 in Phase I trials. Neither compound is FDA-approved. Avoid in pregnancy. Physician oversight required.
Always cleared with your concierge before protocol start.
Regulatory Context
FDA compounding status.
| FDA Status | Risk Level | Compounding | Key Date |
|---|---|---|---|
| PCAC Review July 2026 | 🔴 At Risk | Awaiting PCAC — 503A eligibility review (MOTS-c component) | PCAC July 23, 2026 |
Blend with MOTS-c component under PCAC review. Regulatory posture tracks most restrictive component.
Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.
Pricing
What it costs.
Indicative range for VIP + MOTS-c Blend, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See VIP + MOTS-c Blend pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $150–$226 USD